Skip to content
Life Sciences Series A Founded 2020

Code Biotherapeutics

Developer of gene therapies for rare diseases. The therapies are developed for the treatment of Duchenne muscular dystrophy and type 1 diabetes. The company has a non-viral gene delivery platform 3DNA that delivers genes of all sizes, improves cellular targeting, and reduces immunogenicity. Founded in 2020, headquartered in Hatfield, United States. The company has raised $85.0M in funding at the series a stage. The…

📍 Hatfield, United States · Genomics,

Funding snapshot

Last roundSeries A
Amount$75M
Date7 June 2022
Total raised$85M
Team size22

About

Developer of gene therapies for rare diseases. The therapies are developed for the treatment of Duchenne muscular dystrophy and type 1 diabetes. The company has a non-viral gene delivery platform 3DNA that delivers genes of all sizes, improves cellular targeting, and reduces immunogenicity. Founded in 2020, headquartered in Hatfield, United States. The company has raised $85.0M in funding at the series a stage. The team comprises 22 (Jun 30, 2026) employees. The company operates in the Genomics sector with additional focus on Gene Therapy and Rare Diseases. Its business model centers on Muscle Disorders. Founded in 2020, headquartered in Hatfield, United States. The company has raised $85.0M at the Series A stage. Backed by investors including 4Bio Capital, UPMC, Takeda, New Enterprise Associates, T1D Fund and others.

Business model

Orthopedics > Drugs > Muscle Disorders,

Rare Diseases > Drugs > Musculoskeletal,

Genomics > Applied Genomics > Clinical Genomics > Therapeutics

Institutional investors

4Bio Capital UPMC Takeda New Enterprise Associates T1D Fund CureDuchenne Northpond Ventures UCB Ventures Amgen CureDuchenne Ventures Hatteras Venture Partners UPMC Enterprises

Latest coverage

No articles yet.

Raising like Code Biotherapeutics?

Analyze your pitch deck before your next raise.

Analyze My Deck →